Archives
Please, enter cell line, author or any other phrase or word you would like to search for.
BIOSpektrum application article highlights HoloMonitor technology (in German)
PHI’s CSO, Kersti Alm, and Head of Communication, Lisa Bodily, have recently contributed to the June 2023 issue of the German BIOSpektrum journal. Their application article sheds light on how HoloMonitor’s technology is applied for non-invasive live cell analysis.
Interim Report 4 2022/23
Sales continue to grow, and the year ended up with the highest turnover for a year in PHI, so far.
Notice that Interim Report 4 2022/23 will be published on June 26, 2023
PHI changes the date for publication of Interim Report 4 2022/23 to June 26, 2023.
The PHI Story
Get to know PHI! PHI provides innovative tools that let you continuously image and monitor your cells directly in your incubator.
PHI’s new HoloMonitor M4FL premiers at major scientific conferences
PHI introduces the HoloMonitor M4FL system to the global scientific community at two major scientific conferences this June.
PHI AB’s warrant exercise registered with the Swedish Companies Registration Office
PHI today announces that the new shares from the exercise of warrants of series TO 3 have been registered with the Swedish Companies Registration Office.
PHI is the most innovative MedTech Company in Scandinavia in 2023
We at PHI are humbled that the Global Health & Pharma Magazine has awarded us as the most innovative MedTech Company in Scandinavia in 2023!
Bulletin from extraordinary general meeting in Phase Holographic Imaging PHI AB (publ)
Phase Holographic Imaging PHI AB (publ) held an extraordinary general meeting on 9 May 2023. The following resolutions were passed at the meeting:
TO 3 Warrants Subscribed to 100 %
On 2 May 2023, the exercise period for warrants of series TO 3, which were issued in connection with PHI AB’s rights issue of units that were announced on 22 February 2022, ended. […] The proceeds of the TO 3 warrants amount to approximately SEK 12.7 million before the deduction of transaction-related costs, corresponding to a subscription rate of 100 percent.
Cytocentric measurement for regenerative medicine
PHI, together with our alliance for advancing cell-based biomanufacturing with Wake Forest Institute for Regenerative Medicine, BioSpherix, global analytics company SAS and others, has recently published a paper in Frontiers in Medical Technology about the critical cell and process parameters for cell and tissue products as well as technologies available in Regenerative Medicine. Here we highlighted more about the “what, why and how” of cyctocentric measurement.